ORANTINIB

SynDRA canonical compound SYN0000671 — structure-anchored drug synonym record

Clinical phase	Phase 3
Primary target(s)	AURKA \| AURKB \| EGFR \| FGFR1 \| FGFR2 \| KDR \| PDGFRA \| PDGFRB \| TBK1
Mechanism of action	FGFR inhibitor \| PDGFR tyrosine kinase receptor inhibitor \| VEGFR inhibitor

All known targets

FGFR1
KDR
AURKA
AURKB
FGFR2
PDGFRA
PDGFRB
EGFR
FGFR3
FGFR4
PPARG
TBK1

Mechanisms of action (all sources)

FGFR3 INHIBITOR
Fibroblast growth factor receptor inhibitor
FGFR1 INHIBITOR
FGFR4 INHIBITOR
FGFR2 INHIBITOR
PDGFRB INHIBITOR
Platelet-derived growth factor receptor inhibitor
PDGFRA INHIBITOR
KDR INHIBITOR
Vascular endothelial growth factor receptor 2 inhibitor
FGFR inhibitor
PDGFR tyrosine kinase receptor inhibitor

Drug classes

Protein Kinase Inhibitors

Cross-references

PubChem CID: 5329099
ChEMBL: CHEMBL274654
DrugBank: DB12072
ChEBI: 91088
PDB: SU6
TTD: D0A1AQ

Synonyms

SU-6668
Su006668
NSC-702827
SU-006668
TSU-68
Rosiglitazone + metformin
TSU 68
SU 6668
SU6668
UNII-9RL37ZZ665
Orantinib (TSU-68)
NSC 702827
TSU68
CHEMBL274654
9RL37ZZ665
PDGFR Tyrosine Kinase Inhibitor VI, SU6668
2,4-Dimethyl-5-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-pyrrole-3-propanoic acid
J-502593
Orantinibum
3-(2,4-dimethyl-5-{[(3Z)-2-oxo-1H-indol-3-ylidene]methyl}-1H-pyrrol-3-yl)propanoic acid
3-[2,4-dimethyl-5-[(Z)-(2-oxo-1H-indol-3-ylidene)methyl]-1H-pyrrol-3-yl]propanoic acid
Orantinib [INN]
(Z)-3-(2,4-dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid
Orantinib (SU6668)
TSU-68 (Random Configuration)
3-(4-(2-Carboxyethyl)-3,5-dimethylpyrrol-2-methylidenyl)-2-indolinone
3-(2,4-Dimethyl-5-((2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl)-1H-pyrrol-3-yl)propionic acid
3-{2,4-Dimethyl-5-[(Z)-(2-Oxo-1,2-Dihydro-3h-Indol-3-Ylidene)methyl]-1h-Pyrrol-3-Yl}propanoic Acid
3-(2,4-Dimethyl-5-(2-oxo-1,2-dihydroindol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid
5-((1,2-Dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid
1H-Pyrrole-3-propanoic acid, 5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
1H-Pyrrole-3-propanoic acid, 5-[(Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-
TUS-68
(Z)-3-(2,4-Dimethyl-5-((2-oxoindolin-3-ylidene)-methyl)-1H-pyrrol-3-yl)propanoic acid
1H-Pyrrole-3-propanoic acid, 5-((Z)-(1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-
SU006668
Orantinib; SU-6668
ORANTINIB [WHO-DD]
3-(2,4-Dimethyl-5-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid

Look up ORANTINIB in the interactive SynDRA portal →